[go: up one dir, main page]

MX2020004434A - Formulaciones estables de citomegalovirus. - Google Patents

Formulaciones estables de citomegalovirus.

Info

Publication number
MX2020004434A
MX2020004434A MX2020004434A MX2020004434A MX2020004434A MX 2020004434 A MX2020004434 A MX 2020004434A MX 2020004434 A MX2020004434 A MX 2020004434A MX 2020004434 A MX2020004434 A MX 2020004434A MX 2020004434 A MX2020004434 A MX 2020004434A
Authority
MX
Mexico
Prior art keywords
cytomegalovirus
stable formulations
cmv
polyol
sugar
Prior art date
Application number
MX2020004434A
Other languages
English (en)
Inventor
Muneeswara Babu Medi
Harrison Bradford Davis
Lorenzo H Chen
Lynne Ann Isopi
Jeffrey Thomas Blue
Heidi Joanne Pixley
Erin J Green-Trexler
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020004434A publication Critical patent/MX2020004434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a formulaciones estables de un citomegalovirus (CMV) que comprenden, por ejemplo, un CMV genéticamente modificado que es de replicación condicionalmente defectuosa, un amortiguador, una sal álcali o alcalina, un azúcar, un derivado de celulosa y opcionalmente un poliol.
MX2020004434A 2017-11-01 2018-10-29 Formulaciones estables de citomegalovirus. MX2020004434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580230P 2017-11-01 2017-11-01
PCT/US2018/057914 WO2019089410A1 (en) 2017-11-01 2018-10-29 Stable formulations of cytomegalovirus

Publications (1)

Publication Number Publication Date
MX2020004434A true MX2020004434A (es) 2020-08-06

Family

ID=66332265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004434A MX2020004434A (es) 2017-11-01 2018-10-29 Formulaciones estables de citomegalovirus.

Country Status (10)

Country Link
US (2) US20210299247A1 (es)
EP (1) EP3704233A4 (es)
JP (1) JP7130744B2 (es)
KR (1) KR102753365B1 (es)
CN (1) CN111344397A (es)
AU (1) AU2018361217A1 (es)
BR (1) BR112020008482A8 (es)
CA (1) CA3079828A1 (es)
MX (1) MX2020004434A (es)
WO (1) WO2019089410A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202205231D0 (en) * 2022-04-09 2022-05-25 Nasaleze Patents Ltd Vaccine compositions
CN114990260B (zh) * 2022-06-01 2024-04-26 昆明理工大学 用于检测中枢神经系统感染性病原体的多重荧光定量pcr检测试剂
CN114990240B (zh) * 2022-06-01 2024-05-10 昆明理工大学 用于检测妇科疾病外源病原体的多重qPCR检测试剂
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
EP0919243A1 (en) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
CA2361837C (en) * 1999-02-05 2011-06-07 Merck And Co., Inc. Human papilloma virus vaccine formulations
AU2001288682A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
AU2004299057B2 (en) 2003-12-17 2010-06-24 Wyeth Llc Methods for porducing storage stable viruses and immunogenic compositions thereof
WO2006031264A2 (en) * 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
MY156422A (en) * 2007-04-06 2016-02-26 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
KR20110020804A (ko) 2008-05-13 2011-03-03 유니버시티 오브 워싱톤 치료제의 세포내 전달을 위한 미셀
JP5715051B2 (ja) * 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
AU2009329806A1 (en) * 2008-12-22 2010-07-01 The University Of Queensland Patch production
WO2010138522A2 (en) * 2009-05-26 2010-12-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
US20130189754A1 (en) * 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
AU2013204906B2 (en) * 2012-03-12 2016-01-07 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
BR112014024159A2 (pt) 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
US20150307850A1 (en) * 2012-12-04 2015-10-29 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
US9974850B2 (en) * 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
BR112015021945A8 (pt) * 2013-03-05 2019-12-03 Univ Oregon Health & Science vetores de citomegalovírus humanos ou animais e seus usos
US9782470B2 (en) 2013-10-16 2017-10-10 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
US9907844B2 (en) 2013-12-11 2018-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
JP2017515503A (ja) 2014-05-08 2017-06-15 ファイザー・インク Ｃｍｖを処置するための手段および方法
EP4026568A1 (en) * 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
MA44252A (fr) 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
JP7348063B2 (ja) * 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法

Also Published As

Publication number Publication date
WO2019089410A1 (en) 2019-05-09
CN111344397A (zh) 2020-06-26
RU2020117509A (ru) 2021-12-01
BR112020008482A2 (pt) 2020-10-20
KR20200083540A (ko) 2020-07-08
BR112020008482A8 (pt) 2023-01-31
US20210299247A1 (en) 2021-09-30
CA3079828A1 (en) 2019-05-09
AU2018361217A1 (en) 2020-04-23
RU2020117509A3 (es) 2021-12-21
JP7130744B2 (ja) 2022-09-05
EP3704233A1 (en) 2020-09-09
KR102753365B1 (ko) 2025-01-10
US20230277654A1 (en) 2023-09-07
JP2021501173A (ja) 2021-01-14
EP3704233A4 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
MX2020004434A (es) Formulaciones estables de citomegalovirus.
NI202000039A (es) Formulaciones de composiciones de vacuna contra el vírus del dengue
ZA201807769B (en) Peroxymonosulfate toothpowder composition for tenacious stains
CL2017001188A1 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos.
CR20180034A (es) Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
MX2018006875A (es) Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.
SV2018005643A (es) Composiciones de insulina de rapida accion
MX2016014643A (es) Composiciones de insulina de rapida accion.
CO2019013047A2 (es) Composiciones sólidas para administración oral
IL289094A (en) Tetrazines for increasing the speed and yield of the "click release" reaction
MX2018011322A (es) Sistema y procedimiento de almacenamiento de datos en movimiento.
MX390494B (es) UNA NUEVA SUBPOBLACIÓN DE TREGS CD8+CD45RCbajo Y SUS USOS.
ES2691529T3 (es) Animales con dipeptidil peptidasa iv (dpp4) humanizada
TWD175733S (zh) 錶帶
MX2023003548A (es) Composiciones acuosas que comprenden complejo lupulo-metal.
TWD178832S (zh) 手鍊
GEP20237486B (en) Formulations of copanlisib
BR112018014123A2 (pt) formulação farmacêutica aquosa estável.
WO2016094609A8 (en) Optical cross-coupling mitigation systems for wavelength beam combining laser systems
MX2020004675A (es) Formulaciones de alcohol de seda.
CR20160225A (es) Glicoproteínas recombinantes y sus usos
BR112017001749A2 (pt) tipos de álcool polivinílico em pó, diretamente comprimíveis
MY195384A (en) Two-Component Composition
SG10201909051QA (en) Compositions and methods for live, attenuated alphavirus formulations
MX2020004202A (es) Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.